publication date: Mar. 8, 2019

NCI Trials

NCI Trials for March

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – 10214

Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Lipson, Evan Jacob

(410) 502-5977


Phase I – 10241

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

NCI Center for Cancer Research

Miljkovic, Miloa

(301) 250-5216


Phase I – 10246

A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

University Health Network Princess Margaret Cancer Center LAO

Shafer, Danielle A

(804) 628-0279


Phase I/II – 10195

A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor

Duke University – Duke Cancer Institute LAO

Dees, Elizabeth Claire

(919) 843-7714


Phase I/II – ABTC-1801

Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations

Adult Brain Tumor Consortium

Bindra, Ranjit S

(203) 200-3749


Phase I/II – PBTC-053

A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH … Continue reading NCI Trials for March 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.